跳至主要内容
临床试验/NCT02456454
NCT02456454已完成3 期

Placebo Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder

Nationwide Children's Hospital0 个研究点目标入组 46 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
46
主要终点
Young Mania Rating Scale

研究概览

简要总结

Controlled trial of the efficacy and safety of valproate, versus risperidone in children, ages 3-7 yr. with Bipolar I or II Disorder, mixed, manic or hypomanic episode.

详细描述

The objective of this study was to study the efficacy and safety of valproate, versus risperidone in children, ages 3-7 yr. with Bipolar I or II Disorder, mixed, manic or hypomanic episode.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
3 Years 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Risperidone

Experimental

Risperidone, PO 0.25-2 mg/day

干预措施: Risperidone (Drug)

Valproic

Experimental

Valproic Acid PO to achieve plasma levels of 85-100

干预措施: Valproic Acid (Drug)

Placebo

Placebo Comparator

Liquid placebo PO matched for color and taste.

干预措施: Placebo (Drug)

结局指标

主要结局

Young Mania Rating Scale

时间窗: 6 weeks

Young Mania Rating Scale

次要结局

  • Clinical Global Improvement Scale(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Robert Kowatch

MD

Nationwide Children's Hospital

相似试验